Coherus BioSciences
$22.019876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$22.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.05 (0.23%) Today
$0.00 (0.00%) As of 4:09 PM EDT after-hours
Why Robinhood?
You can buy or sell CHRS and other stocks, options, ETFs, and crypto commission-free!
About CHRS
Coherus BioSciences, Inc. Common Stock, also called Coherus BioSciences, is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Read More Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar, and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
Employees
232
Headquarters
Redwood City, California
Founded
2010
Market Cap
1.54B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
812.25K
High Today
$22.33
Low Today
$21.52
Open Price
$21.90
Volume
1.05M
52 Week High
$23.43
52 Week Low
$8.32
Collections
CHRS News
Price Paid on Robinhood
37% Higher
Right Now
52 Week Low
$8.32
Average Price Paid
$16.02
52 Week High
$20.66
Analyst Ratings
100%
of 7 ratings
Buy
100%
Hold
0%
Sell
0%
CHRS Earnings
-$0.92
-$0.51
-$0.09
$0.32
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
—
Actual
Expected Nov 7, After Hours